MMPs in the gut: inflammation hits the matrix

Schuppan, Detlef; Hahn, Eckart G.

doi:10.1136/gut.47.1.12

Cited by 60 publications

(38 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sequestration of MMP-2 to ECM of intestinal IBD tissue may also partially contribute to the paradoxical phenomenon, i.e., the elevated expression of MMP-2 in inflamed tissue and low level in the circulation. 18 MMP-2 is constitutively expressed by many cells, especially mesenchymal cells, such as fibroblasts and endothelial cells, and has a ubiquitous tissue distribution. 20 TNF-␣ and other proinflammatory cytokines seem not to be major promoting factors for the expression of MMP-2 because the gene promoter lacks TPA-responsive element (TRE).…”

Section: Discussionmentioning

confidence: 99%

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohnʼs disease

Gao

Meijer

Schlüter

et al. 2007

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohnʼs disease

Gao

Meijer

Schlüter

et al. 2007

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…As we demonstrated recently, elevated plasma concentration of TGF-β 1 , known as TIMP-1 stimulator, was related to inflammation activity and should be considered as a possible biomarker in UC patients [11,12] . According to Sch ppan and Hahn [10] blockade of certain MMPs could be a novel th rapeutic approach, and therefore some novel mucosa derived parameters, such as MMP-1 and TIMP-1, may prove useful to assess prognosis, disease activity, and treatment response in inflammatory bowel disease.…”

Section: Introductionmentioning

confidence: 99%

Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 as biomarkers of ulcerative colitis activity

Wiercińska–Drapało

Jaroszewicz²,

Flisiak³

et al. 2003

WJG

View full text Add to dashboard Cite

AIM:Overexpression of mucosal metalloproteinases (MMP) have been demonstrated recently in inflammatory bowel disease. Their activity can be counterbalanced by the tissue inhibitor of metalloproteinases (TIMP). The aim of this study was to evaluate the effect of ulcerative colitis (UC) on MMP-1 and TIMP-1 plasma concentrations, as two possible biomarkers of the disease activity. METHODS:MMP-1 and TIMP-1 plasma concentrations were measured with an enzyme immunoassay in 16 patients with endoscopically confirmed active UC. RESULTS:Plasma concentrations of both MMP-1 (13.7±0.2 ng/ml) and TIMP-1 (799±140 ng/ml) were significantly elevated in UC patients in comparison to healthy controls (11.9±0.9 ng/ml and 220±7 ng/ml respectively). There was no correlation between TIMP-1 and MMP-1 concentrations (r=-0.02). TIMP-1 levels revealed significant positive correlations with scored endoscopic degree of mucosal injury, disease activity index and clinical activity index values as well as C-reactive protein concentration. There was no correlation between MMP-1 and laboratory, clinical or endoscopic indices of the disease activity. CONCLUSION:These results confirm the role of both MMP-1 and TIMP-1 in the pathogenesis of ulcerative colitis. However only TIMP-1 can be useful as a biomarker of the disease activity, demonstrating association with clinical and endoscopic pictures.Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 as biomarkers of ulcerative colitis activity.

show abstract

“…MMP2 was identified as a candidate gene for IBD on the basis of its physical location in a region of strong genetic linkage to the disease (Hampe et al 1999), its role in inflammatory processes and extracellular matrix turnover (Schuppan & Hahn, 2000) and evidence of abnormal expression of in gut biopsies obtained from IBD patients (Baugh et al 1999). Matrix metalloproteinase 2 (MMP2, MIM 120360) is a member of a family of metalloproteinases involved in the breakdown of extracellular matrix in normal and pathophysiological processes such as tissue remodelling, vascularization, inflammation, arthritis and metastasis.…”

Section: Mmp2 Sequence Variants and Genotypingmentioning

confidence: 99%

SNP Subset Selection for Genetic Association Studies

Byng¹,

Whittaker

Cuthbert³

et al. 2003

Annals of Human Genetics

View full text Add to dashboard Cite

SummaryAssociation studies for disease susceptibility genes rely on the high density of SNPs within candidate genes. However, the linkage disequilibrium between SNPs imply that not all SNPs identified in the candidate region need be genotyped. Here we develop several approaches to SNP subset selection, which can substantially reduce the number of SNPs to be genotyped in an association study. We apply clustering algorithms to pairwise linkage disequilibrium measures, with SNP subsets determined for different cut-off values of using nearest and furthest neighbour clusters. Alternatively, SNP subsets may be determined by the proportion of haplotypes they identify. We also show how power calculations, based on the average power to identify a SNP as the disease susceptibility mutation using haplotype-based or logistic regression based statistical analyses, can be used to choose SNP subsets. All these methods provide a ranking method for subsets of a specific size, but do not provide criteria for overall choice of SNP subset size. We develop such criteria by incorporating power calculations into a decision analysis, where the choice of SNP subset size depends on the genotyping costs and the perceived benefits of identifying association. These methods are illustrated using eleven SNPs in the MMP2 gene.

show abstract

MMPs in the gut: inflammation hits the matrix

Cited by 60 publications

References 8 publications

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohnʼs disease

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohnʼs disease

Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 as biomarkers of ulcerative colitis activity

SNP Subset Selection for Genetic Association Studies

Contact Info

Product

Resources

About